|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||77.16 - 78.47|
|52 Week Range||72.87 - 89.74|
|Beta (5Y Monthly)||0.31|
|PE Ratio (TTM)||16.78|
|Earnings Date||Jan 31, 2024 - Feb 05, 2024|
|Forward Dividend & Yield||3.00 (3.83%)|
|Ex-Dividend Date||Dec 14, 2023|
|1y Target Est||89.76|
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
NORTHAMPTON, MA / ACCESSWIRE / December 1, 2023 / Nearly 36 years ago the AIDS Memorial Quilt was displayed for the first time to memorialize and physically represent lives lost to HIV. Gilead has always actively supported the Quilt, and creating ...
FOSTER CITY, Calif., November 30, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.